Clinical trial · Interventional
Identification and Evaluation of Biomarkers of Resistance to Neoadjuvant Chemotherapy (IDEA SEIN)
Identification and Evaluation of Biomarkers of Resistance to Neoadjuvant Chemotherapy and Establishment of Preclinical Models of Resistance in Locally Advanced Breast Cancer
NCT03255486CI-TRIAL-00029168IDEASEINcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Biomarkers of resistance to neoadjuvant chemotherapy in locally advanced breast cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sample | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Blood sample
- description
- Blood samples will be taken by venipuncture during the initial assessment (4 tubes of 5 ml at diagnosis and 3 tubes of 5 ml to the following) These blood tests will be repeated after the first course, at the end of neoadjuvant chemotherapy and after surgery and will be carried out jointly to levies motivated by the balance sheet or the treatment of CS to avoid additional puncture. These samples will allow us to study the profiles of circulating tumor DNA, and miRNA tumor proteins (proteomics study).
- interventionNames
- Biological: Blood sample
Primary outcomes (1)
- measure
- predictive molecular abnormalities assessment
- timeFrame
- up to 5 years
- description
- Highlighting and study of predictive molecular abnormalities of resistance to neoadjuvant chemotherapy in locally advanced breast cancer
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * proven invasive breast adenocarcinoma (cytology and / or biopsy). * locally advanced stage (tumor size greater than 2 cm). * neoadjuvant chemotherapy indication validated RCP * Patient eligible for neoadjuvant chemotherapy. * Performance Index according to WHO or less 1. * Patient aged 18 years and older. * Being affiliated to a social security scheme or an equivalent scheme of social protection * Obtaining signed informed consent, and that before any specific prequalification testing. Exclusion Criteria: * presence of metastatic disease at diagnosis. * Breast Cancer inflammatory. * rare histologic subtypes (non ductal lobular and not). * Other cancer (except basal cell skin carcinoma and cancer of the cervix in situ adequately treated and curative) treated in the previous 5 years. * Patient pregnant or nursing or of childbearing age without effective contraception. * Breast cancer in men. * legal incapacity or limited legal capacity. medical or psychological conditions allowing the subject to complete the study or to sign the consent (art. L.1121-6, L.1121-7, L.1211-8, L1211-9).
References
Publications (0)
Data not yet available
No reference posted for this study.